By: IPP Bureau
Last updated : September 01, 2026 1:48 pm
Belgian biotech to complete preclinical development, prepare lead candidate for GMP manufacturing and double its R&D team
Belgian biotechnology company Amyl Therapeutics has raised €8.25 million (US$9.4 million) through an extension of its Series A financing to advance its preclinical-stage platform targeting amyloid-related neurodegenerative diseases.
The financing was split equally between public grants and private investment, with participation from new family offices and business angels, as well as existing shareholders including Noshaq and Mérieux Equity Partners.
The company said the funding will support the completion of development of its fully characterised clinical candidate and preparation for GMP manufacturing, while enabling the generation of additional in vivo efficacy and safety data required to further validate its platform.
The financing also marks an expansion phase for Amyl Therapeutics. One of the new lead family-office investors will join the company's board, while the company is expanding its laboratory facilities at the LegiaPark life sciences campus in Liège, Belgium. It also plans to double the size of its R&D team.
Amyl Therapeutics is developing a pan-amyloid immunotherapy platform designed to target multiple pathological protein aggregates implicated in neurodegenerative diseases.
Unlike conventional antibody therapies that typically target a single pathological protein, Amyl Therapeutics' lead fusion protein is designed to recognise a common amyloid structure shared by toxic aggregates involving amyloid beta, tau and alpha-synuclein.
These proteins are associated with diseases including Alzheimer's and Parkinson's.
Pierre Vandepapelière, co-founder, CEO and CMO, Amyl Therapeutics, said the financing represents an important endorsement of the company's scientific approach and development strategy.
“Our results already demonstrate that our fusion protein combines the therapeutic strengths of three monoclonal antibodies while addressing many key limitations in brain delivery and safety,” he said.
Valérie Calenda, Managing Partner, Mérieux Equity Partners, said Amyl Therapeutics' platform has the potential to reshape approaches to neurodegenerative disease treatment.
She added that the latest financing would provide the company with the resources required to generate critical data and advance its clinical development pathway.